कृपया अन्य खोज का प्रयास करें
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Joel D. Baines | - | - | Member of Scientific Advisory Board |
Dedra Stefanie Buchwald | - | - | Member of Scientific Advisory Board |
Greg Duncan | 56 | 2018 | Chairman & CEO |
Lesley Mussio Arnold | - | - | Member of Scientific Advisory Board |
Michael C. Camilleri | - | - | Member of Scientific Advisory Board |
David R. Keefer | 70 | 2018 | Independent Director |
Richard James Whitley | 77 | 2020 | Member of Scientific Advisory Board & Independent Director |
Daniel J. Clauw | - | - | Chair of Scientific Advisory Board |
William L. Pridgen | 62 | 2012 | Founder & Director |
Abel De La Rosa | 60 | 2020 | Independent Director |
John C. Thomas | 69 | 2020 | Independent Director |
Richard Alan Burch | 67 | 2014 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है